## Diagnostic Criteria & Next Step in HCC Management **Key Point:** A nodule ≥1 cm in a cirrhotic liver with arterial phase enhancement and washout on one imaging modality (CT or MRI) in the setting of elevated AFP (>200 ng/mL) meets diagnostic criteria for HCC and does NOT require biopsy confirmation. ### AASLD/EASL Diagnostic Algorithm | Nodule Size | Imaging Criteria | AFP | Diagnosis | |---|---|---|---| | >1 cm | Arterial enhancement + washout on 1 imaging | Any | HCC | | >1 cm | Arterial enhancement + washout on 2 imaging | Any | HCC | | >1 cm | Arterial enhancement alone | >400 ng/mL | HCC | | <1 cm | Any imaging | Any | Surveillance | **High-Yield:** Once HCC is diagnosed, the next step is staging (TNM, BCLC) and treatment planning, NOT further diagnostic imaging or biopsy. ### Why TACE is the Next Step Here 1. **BCLC staging:** This patient has a solitary lesion <5 cm with preserved liver function (Child B) → **BCLC stage A** (early HCC) 2. **Treatment algorithm for BCLC A:** TACE is first-line for lesions 1–5 cm in patients with adequate liver function 3. **Curative intent:** TACE offers 2-year survival >60% in early-stage disease **Clinical Pearl:** The combination of CT imaging findings + AFP >200 ng/mL + cirrhosis is diagnostic; biopsy adds no value and delays treatment. **Tip:** Always apply AASLD/EASL criteria before ordering additional imaging or invasive tests. 
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.